On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 700,000. No changes were recorded in authorized or issued share capital during the month.

As of 31 January 2026, the company had 991,874,320 issued shares (excluding treasury shares) and 7,084,210 treasury shares, summing to 998,958,530 total shares. The public float requirement was satisfied. No increase or decrease in either issued shares or treasury shares took place in January 2026.

Under the existing share option schemes, outstanding share options were unchanged, and there were no exercises resulting in new share issuance or treasury share transfers in January 2026. The warrants and other convertible instruments sections were marked not applicable. Repurchases of 800,000 shares in April 2025 and 4,986,000 shares between October and December 2025 remained not yet cancelled as of 31 January 2026.